
M&A Stories
June 3, 2026
The Delaware Supreme Court reminded us of its strong contractarian philosophy. In a reversal of a Delaware Court of Chancery decision, the high court held that the implied covenant of good faith and fair dealing could not save the sellers’ $400 million milestone earnout by requiring the buyer to pursue a government approval pathway that was not the earnout milestone pathway specified in the merger agreement.
The case involved the sale of a surgical robot startup. The sellers would receive a $400 million earnout if one of its surgical robots received a 510(k) clearance from the FDA by the end of 2021.
After the acquisition, the FDA shifted the approval process for the startup’s robot to a De Novo review, a more complex pathway requiring clinical data due to its novel design. What makes this particularly striking is that the buyer’s own internal analysts initially concluded the switch would cause only about a sixty-day delay for this specific robot — meaning the alternate pathway was not dramatically more burdensome. Yet the buyer chose to abandon the earnout entirely, arguing that the milestones were tied to the easier pathway, which was no longer available.
The sellers sued the buyer in the Delaware Court of Chancery and convinced the court that the buyer had breached its implied duty of good faith and fair dealing. The court held that although the FDA closed the 510(k) regulatory pathway that the milestones referred to, the implied covenant required the buyer to pursue the alternate De Novo pathway for this regulatory milestone and to treat that approval as the functional equivalent of the 510(k) clearance specified in the contract.
The buyer appealed to the Delaware Supreme Court, and the high court reversed. It held that the implied covenant of good faith and fair dealing is reserved for developments that could not be anticipated, not developments that the parties simply failed to consider, and it cannot be invoked as an equitable remedy for rebalancing economic interests after events that could have been anticipated but were not. The court noted that the possibility of the FDA switching pathways was foreseeable — the parties were sophisticated, the FDA had publicly signaled it was modernizing its approval process before the deal was signed, and the sellers had even received direct feedback from the FDA raising doubts about the 510(k) pathway for this specific robot before closing. The sellers could have negotiated contract language providing that any equivalent government approval would trigger the earnout. They did not.
If your earnout depends on a government approval, make sure the contract accounts for what happens if that approval comes through a different door than expected. Once again, the Delaware Supreme Court reminds sophisticated buyers and sellers that you must live with the contract you negotiated.
Case: Johnson & Johnson v. Fortis Advisors LLC, 352 A.3d 229 No. 490, 2024, Supreme Court of Delaware, (January 12, 2026)
Thank you for reading this blog. If you have any questions, insights, or if you’d like to engage in a more detailed discussion on this matter, I invite you to reach out directly.
Feel free to send me an email. I value thoughtful discussions and am always open to connecting with business owners, management, as well as professionals who share an interest in the complexities of M&A law in lower middle market private target deals.
By John McCauley: I write about recent problems of buyers and sellers in lower middle market private target deals.
Email: jmccauley@mk-law.com
Profile: http://www.martindale.com/John-B-McCauley/176725-lawyer.htm
Telephone: 714 273-6291
Check out my books: Buying Established Business Assets: A Guide for Owners, https://www.amazon.com/dp/B09TJQ5CL5
and Advisors and Selling Established Business Assets: A Guide for Owners and Advisors, https://www.amazon.com/dp/B0BPTLZNRM
Legal Disclaimer
The blogs on this website are provided as a resource for general information for the public. The information on these web pages is not intended to serve as legal advice or as a guarantee, warranty or prediction regarding the outcome of any particular legal matter. The information on these web pages is subject to change at any time and may be incomplete and/or may contain errors. You should not rely on these pages without first consulting a qualified attorney.

Recent Comments